news | MaaT Pharma

Press Releases

MaaT Pharma Expands Executive Team to Strengthen Corporate Development and Accelerate Expansion of Microbiome Data Science Platform GutPrint

Jean-Marc Renard, MS, MBA, joins as Chief Business Officer Emmanuel Prestat, PhD, joins as Computational…

mrossettiSeptember 10, 2019

Posters

An evaluation of binning methods to recover human gut microbial pan-genomes from non-redundant reference gene catalog

mrossettiJuly 24, 2019

Press Releases

MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics

Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute…

mrossettiJune 24, 2019

Business Update

Statement following recently FDA reported event with FMT in USA

We recognize that the FDA has sent out an alert regarding the death of a…

mrossettiJune 14, 2019

Business Update

Communication suite à l’alerte de sécurité rapportée par la FDA sur un décès lié à une FMT aux Etats-Unis

Nous avons pris note de l’alerte lancée par la FDA (USA) concernant le décès d'un…

mrossettiJune 14, 2019

Press Releases

MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform

- First patents to cover the fundamental processes for accessing the human gut microbiome as…

mrossettiMay 21, 2019

Press Releases

IMM-ETG – A New European Initiative for Intestinal Microbiome Medicinal Products

“Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute…

mrossettiMay 21, 2019

Press Releases

MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD

MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute…

mrossettiApril 9, 2019

Posters

HERACLES: A Phase II single-arm prospective study to assess the efficacy of Fecal Microbiota Transfer (FMT) in the treatment of steroid-refractory gastro-intestinal predominant aGVHD post allo-hsct

mrossettiMarch 26, 2019

Media

MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients

mrossettiFebruary 6, 2019

MaaT Pharma Expands Executive Team to Strengthen Corporate Development and Accelerate Expansion of Microbiome Data Science Platform GutPrint

An evaluation of binning methods to recover human gut microbial pan-genomes from non-redundant reference gene catalog

MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics

Statement following recently FDA reported event with FMT in USA

Communication suite à l’alerte de sécurité rapportée par la FDA sur un décès lié à une FMT aux Etats-Unis

MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform

IMM-ETG – A New European Initiative for Intestinal Microbiome Medicinal Products

MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD

HERACLES: A Phase II single-arm prospective study to assess the efficacy of Fecal Microbiota Transfer (FMT) in the treatment of steroid-refractory gastro-intestinal predominant aGVHD post allo-hsct

MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients

Categories

MAAT PHARMA

COMPANY

RESSOURCES

CONTACT